Blood Test for Early-Onset Alzheimer's Disease Relies on Exosomal MicroRNA Biomarkers
By LabMedica International staff writers Posted on 09 Nov 2014 |
A team of Australian biomedical researchers has devised a blood test based on expression profiling of small non-coding RNA’s, microRNA (miRNA), for the diagnosis of early-onset Alzheimer's disease (AD).
Investigators at the University of Melbourne (Australia) identified a set of differential exosomal miRNA biomarkers that differentiate between healthy individuals and AD patients. They adapted a panel of these miRNAs—snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA—obtained from small serum vesicles known as exosomes for screening of potential AD sufferers.
For this purposed they used a next-generation deep sequencing technique to profile exosomal miRNA from serum collected from 49 participants in the Australian Imaging, Biomarkers, and Lifestyle Flagship Study (AIBL). Sequencing results were validated using quantitative reverse transcription PCR (qRT-PCR). Additional risk factors collected during the 4.5-year AIBL Study including clinical, medical, and cognitive assessments, and amyloid neuroimaging with positron emission tomography were assessed.
An AD-specific 16-miRNA signature was selected, and adding established risk factors including age, sex, and apolipoprotein epsilon-4 (APOE epsilon-4) allele status to the miRNA panel resulted in a sensitivity and specificity of 87% and 77%, respectively, for predicting AD.
First author Dr. Lesley Cheng, a post-doctoral researcher in biochemistry, molecular and cell biology at the University of Melbourne, said, “This test provides the possibility of early detection of AD by using a simple blood test which has been designed to also be cost-effective. Furthermore, it is highly accessible for patients and physicians compared to organizing a brain scan or undergoing a neuropsychological test. Patients with a family history of AD or those with memory concerns could be tested during a standard health check at a medical clinic. This test could ease concerns for patients experiencing normal memory problems due to natural ageing. Those identified as high risk could then be monitored by their doctor."
The miRNA biomarker study was published in the October 28, 2014, online edition of the journal Molecular Psychiatry.
Related Links:
University of Melbourne
Investigators at the University of Melbourne (Australia) identified a set of differential exosomal miRNA biomarkers that differentiate between healthy individuals and AD patients. They adapted a panel of these miRNAs—snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA—obtained from small serum vesicles known as exosomes for screening of potential AD sufferers.
For this purposed they used a next-generation deep sequencing technique to profile exosomal miRNA from serum collected from 49 participants in the Australian Imaging, Biomarkers, and Lifestyle Flagship Study (AIBL). Sequencing results were validated using quantitative reverse transcription PCR (qRT-PCR). Additional risk factors collected during the 4.5-year AIBL Study including clinical, medical, and cognitive assessments, and amyloid neuroimaging with positron emission tomography were assessed.
An AD-specific 16-miRNA signature was selected, and adding established risk factors including age, sex, and apolipoprotein epsilon-4 (APOE epsilon-4) allele status to the miRNA panel resulted in a sensitivity and specificity of 87% and 77%, respectively, for predicting AD.
First author Dr. Lesley Cheng, a post-doctoral researcher in biochemistry, molecular and cell biology at the University of Melbourne, said, “This test provides the possibility of early detection of AD by using a simple blood test which has been designed to also be cost-effective. Furthermore, it is highly accessible for patients and physicians compared to organizing a brain scan or undergoing a neuropsychological test. Patients with a family history of AD or those with memory concerns could be tested during a standard health check at a medical clinic. This test could ease concerns for patients experiencing normal memory problems due to natural ageing. Those identified as high risk could then be monitored by their doctor."
The miRNA biomarker study was published in the October 28, 2014, online edition of the journal Molecular Psychiatry.
Related Links:
University of Melbourne
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans